35582-13-9Relevant academic research and scientific papers
Four-gear ring metal platinum (II) complex phosphorescent luminescent materials
-
Paragraph 0060; 0063, (2017/11/16)
The invention discloses four-gear ring metal platinum (II) phosphorescent luminescent materials as shown in a formula (I) in the specification, wherein a five-membered heterocyclic aromatic group Ar is as shown in the specification; Ar is selected from one of the following: 2H-1,2,3-triazole, X1=N, X2=N, X3=CH); 1H-1,2,3-triazole, X1=CH, X2=N, X3=N; 1,3,4-oxadiazole, X1=O, X2=C, X3=N; oxazole, X1=O, X2=C, X3=CH; or thiazole, X1=S, X2=C, X3=CH. One or more of the four-gear ring metal platinum (II) phosphorescent luminescent materials disclosed by the invention are applied to a luminescent layer of an organic illuminator. The four-gear ring metal platinum (II) phosphorescent luminescent materials disclosed by the invention have strong molecular rigidity, can effectively reduce energy consumed owing to molecular vibration, and have high phosphorescent quantum efficiency, good chemical stability and good heat stability.
Four-tooth-ring metal palladium (II) complex phosphorescent material
-
Paragraph 0061; 0063, (2018/03/24)
The invention discloses a four-tooth-ring metal palladium (II) complex phosphorescent material represented by a formula (I), wherein a pentabasic heteromatic group Ar is formula (shown in the description) and is selected from one of the following formulae: 2H-1,2,3-triazole, wherein X1 is equal to N, X2 is equal to N, and X3 is equal to CH); 1H-1,2,3-triazole, wherein X1 is equal to CH, X2 is equal to N, and X3 is equal to N; oxazole, wherein X1 is equal to O, X2 is equal to C, and X3 is equal to CH; thiazole, X1 is equal to S, X2 is equal to C, and X3 is equal to CH; or N-methylimidazole, wherein X1 is equal to N-Me, X2 is equal to C, and X3 is equal to CH). The four-tooth-ring metal palladium (II) complex phosphorescent material is strong in molecular rigidity, capable of effectively reducing energy consumed by molecular vibration, high in phosphorescent quantum efficiency and good in chemical stability and thermal stability and can be applied to luminescent layers of organic luminescent devices.
3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: Design, synthesis and 3D-QSAR studies
Kaesnaenen, Heikki,Myllymaeki, Mikko J.,Minkkilae, Anna,Kataja, Antti O.,Saario, Susanna M.,Nevalainen, Tapio,Koskinen, Ari M. P.,Poso, Antti
scheme or table, p. 213 - 231 (2010/11/18)
Carbamates are a well-established class of fatty acid amide hydrolase (FAAH) inhibitors. Here we describe the synthesis of meta-substituted phenolic N-alkyl/aryl carbamates and their in vitro FAAH inhibitory activities. The most potent compound, 3-(oxazol-2yl)phenyl cyclohexylcarbamate (2a), inhibited FAAH with a sub-nanomolar IC50 value (IC50=0.74 nM). Additionally, we developed and validated three-dimensional quantitative structure-activity relationships (QSAR) models of FAAH inhibition combining the newly disclosed carbamates with our previously published inhibitors to give a total set of 99 compounds. Prior to 3D-QSAR modeling, the degree of correlation between FAAH inhibition and in silico reactivity was also established. Both 3D-QSAR methods used, CoMSIA and GRID/GOLPE, produced statistically significant models with coefficient of correlation for external prediction (R2 PRED) values of 0.732 and 0.760, respectively. These models could be of high value in further FAAH inhibitor design.
HETEROCYCLIC PHENYL CARBAMATES AS NOVEL FAAH-INHIBITORS
-
Page/Page column 44, (2008/12/08)
Fatty acid amide hydrolase inhibitors of the Formula (I) are provided, wherein R is a heterocyclic or heterocyclic carbonyl moiety and R' is a group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted
New potent C2-symmetric malaria plasmepsin I and II inhibitors.
Oscarsson, Karin,Oscarson, Stefan,Vrang, Lotta,Hamelink, Elizabeth,Hallberg, Anders,Samuelsson, Bertil
, p. 1235 - 1246 (2007/10/03)
A series of malaria plasmepsin (Plm) I and II inhibitors containing a C(2)-symmetric core structure have been synthesised and tested for protease inhibition activity. These compounds can be prepared using a straightforward synthesis involving a phenol nuc
